Delcath Systems (NASDAQ:DCTH) Shares Up 9.3% After Analyst Upgrade

Delcath Systems, Inc. (NASDAQ:DCTH) shares rose 9.3% during trading on Monday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The stock traded as high as $16.46 and last traded at $16.51. 1,011,482 shares traded hands during trading, an increase of 113% from the average session volume of 475,969 shares. The stock had previously closed at $15.11.

DCTH has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research note on Friday. BTIG Research increased their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.17.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Zacks upgraded Delcath Systems from “Hold” to “Strong Buy,” reinforcing the stock’s recent momentum and potentially attracting additional buying interest. Zacks.com
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $32 price target while sharply raising its earnings forecasts. Its FY2026 EPS estimate improved to a loss of $0.17 from a loss of $0.88, and its FY2027 estimate moved to positive $0.12 from a loss of $1.23.
• Positive Sentiment: The longer-term outlook also improved materially: HC Wainwright raised projected EPS to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030. These revisions suggest expectations for accelerating profitability and support the analyst target’s implied upside.
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable earnings-estimate revisions. Separately, the average Wall Street price target indicates approximately 42.8% potential upside, although price-target reliability can vary. Zacks momentum stock article Zacks analyst price target article
• Neutral Sentiment: Reported short interest was listed at zero shares on both August 11 and July 27, with a zero-day short-interest ratio. Because the data shows no actual short position and includes an invalid “NaN” change, it provides little meaningful trading insight.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in shares of Delcath Systems during the 2nd quarter valued at about $1,362,000. Bank of America Corp DE grew its holdings in shares of Delcath Systems by 54.0% in the first quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock valued at $536,000 after purchasing an additional 20,249 shares during the period. Royal Bank of Canada increased its position in Delcath Systems by 14.8% during the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after purchasing an additional 2,364 shares during the last quarter. Sei Investments Co. raised its stake in Delcath Systems by 100.0% during the first quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after purchasing an additional 22,029 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in Delcath Systems during the first quarter worth about $306,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 2.9%

The company has a market capitalization of $580.03 million, a price-to-earnings ratio of 1,672.47 and a beta of 0.52. The firm’s fifty day simple moving average is $12.61 and its two-hundred day simple moving average is $10.97.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. As a group, analysts forecast that Delcath Systems, Inc. will post -0.17 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.